A treat-to-target strategy in inflammatory bowel disease(IBD)involves treatment intensification in order to achieve a pre-determined endpoint.Such uniform and tight disease control has been demonstrated to improve cli...A treat-to-target strategy in inflammatory bowel disease(IBD)involves treatment intensification in order to achieve a pre-determined endpoint.Such uniform and tight disease control has been demonstrated to improve clinical outcomes compared to treatment driven by a clinician’s subjective assessment of symptoms.However,choice of treatment endpoints remains a challenge in management of IBD via a treat-to-target strategy.The treatment endpoints for ulcerative colitis(UC),recommended by the Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE)consensus have changed somewhat over time.The latest STRIDE-II consensus advises immediate(clinical response),intermediate(clinical remission and biochemical normalisation)and long-term treatment(endoscopic healing,absence of disability and normalisation of health-related quality of life,as well as normal growth in children)endpoints in UC.However,achieving deeper levels of remission,such as histologic normalisation or healing of the gut barrier function,may further improve outcomes among UC patients.Generally,all medical therapy should seek to improve short-and long-term mortality and morbidity.Hence treatment endpoints should be chosen based on their ability to predict for improvement in short-and long-term mortality and morbidity.Potential benefits of treatment intensification need to be weighed against the potential harms within an individual patient.In addition,changing therapy that has achieved partial response may lead to worse outcomes,with failure to recapture response on treatment reversion.Patients may also place different emphasis on certain potential benefits and harms of various treatments than clinicians,or may have strong opinions re certain therapies.Potential benefits and harms of therapies,incremental benefits of achieving deeper levels of remission,as well as uncertainties of the same,need to be discussed with individual patients,and a treatment endpoint agreed upon with the clinician.Future research should focus on quantifying the incremental benefits and risks of achieving deeper levels of remission,such that clinicians and patients can make an informed decision about appropriate treatment end-point on an individual basis.focus on quantifying the incremental benefits and risks of achieving deeper levels of remission,such that clinicians and patients can make an informed decision about appropriate treatment end-point on an individual basis.展开更多
针对局部均值分解(Local Mean Decomposition,LMD)算法应用于电能质量扰动检测时存在“端点效应”与滑动平均收敛速度慢,严重影响测量精度的问题,提出一种改进局部均值分解方法(Modified LMD,MLMD)。通过分段三次Hermite插值取代滑动平...针对局部均值分解(Local Mean Decomposition,LMD)算法应用于电能质量扰动检测时存在“端点效应”与滑动平均收敛速度慢,严重影响测量精度的问题,提出一种改进局部均值分解方法(Modified LMD,MLMD)。通过分段三次Hermite插值取代滑动平均法,有效改善LMD收敛慢、受平滑长度影响的弊端。为避免延拓长度不够而导致的“延拓失败”情形,在镜像延拓法的基础上结合“奇延拓”方法提出改进镜像延拓法。针对“直接法”求频率存在“毛刺现象”的弊端,文中改用希尔伯特变换(Hilbert Transform,HT)求取瞬时频率。最后,将MLMD分别应用于单一扰动信号与复合谐波信号的检测,相较传统的经验模态分解方法(Empirical Mode Decomposition,EMD),MLMD方法可有效抑制“端点效应”,同时能更准确的定位扰动信号的起止时刻,并且对高次谐波信号有更好的提取能力。展开更多
目前,国内外很多厂商推出了Linux系统中的终端检测响应(Endpoint Detection and Response,EDR)系统,为云平台、物联网、大数据计算等基础设施提供全面的安全检测和防护服务。但是,针对EDR文件防护功能的绕过攻击能够帮助恶意行为规避监...目前,国内外很多厂商推出了Linux系统中的终端检测响应(Endpoint Detection and Response,EDR)系统,为云平台、物联网、大数据计算等基础设施提供全面的安全检测和防护服务。但是,针对EDR文件防护功能的绕过攻击能够帮助恶意行为规避监控,造成严重的系统和数据安全风险。针对开源和商业闭源的Linux EDR系统,首先,阐述了文件防护功能的底层实现机制,对其核心技术原理进行了分析;其次,重点梳理了4种现有公开的文件防护绕过技术,提出了3种尚未公开的绕过技术,并且总结提炼为3种攻击类型;再次,基于上述绕过技术编写了验证工具,通过测试证明了这些技术方法对于部分Linux EDR系统的文件防护绕过能力;最后,给出了相应的安全防护建议。展开更多
文摘A treat-to-target strategy in inflammatory bowel disease(IBD)involves treatment intensification in order to achieve a pre-determined endpoint.Such uniform and tight disease control has been demonstrated to improve clinical outcomes compared to treatment driven by a clinician’s subjective assessment of symptoms.However,choice of treatment endpoints remains a challenge in management of IBD via a treat-to-target strategy.The treatment endpoints for ulcerative colitis(UC),recommended by the Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE)consensus have changed somewhat over time.The latest STRIDE-II consensus advises immediate(clinical response),intermediate(clinical remission and biochemical normalisation)and long-term treatment(endoscopic healing,absence of disability and normalisation of health-related quality of life,as well as normal growth in children)endpoints in UC.However,achieving deeper levels of remission,such as histologic normalisation or healing of the gut barrier function,may further improve outcomes among UC patients.Generally,all medical therapy should seek to improve short-and long-term mortality and morbidity.Hence treatment endpoints should be chosen based on their ability to predict for improvement in short-and long-term mortality and morbidity.Potential benefits of treatment intensification need to be weighed against the potential harms within an individual patient.In addition,changing therapy that has achieved partial response may lead to worse outcomes,with failure to recapture response on treatment reversion.Patients may also place different emphasis on certain potential benefits and harms of various treatments than clinicians,or may have strong opinions re certain therapies.Potential benefits and harms of therapies,incremental benefits of achieving deeper levels of remission,as well as uncertainties of the same,need to be discussed with individual patients,and a treatment endpoint agreed upon with the clinician.Future research should focus on quantifying the incremental benefits and risks of achieving deeper levels of remission,such that clinicians and patients can make an informed decision about appropriate treatment end-point on an individual basis.focus on quantifying the incremental benefits and risks of achieving deeper levels of remission,such that clinicians and patients can make an informed decision about appropriate treatment end-point on an individual basis.
